EUVIMEDEUVIMED entdecken
Crossref

Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis

Qiujing Chen, Jingmeng Liu, Rosalinda Madonna, Feifei Li, Shuai Chen, Leying Li, Xinrui Wu, Yipaerguli Maimati, Fenghua Ding, Xiaoqun Wang, Ying Shen, Ruiyan Zhang und 4 weitere

Cardiovascular Research · 2025

DOI: 10.1093/cvr/cvaf192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Qiujing Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Hauptthemen laut MEDLINE: Neointima, Vascular System Injuries, Myocytes, Smooth Muscle, Muscle, Smooth, Vascular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Vasostatin-2, a bioactive peptide derived from chromogranin A, has cardiovascular-protective and anti-inflammatory properties. However, its role in injury-induced vascular remodelling remains unclear. This study aimed to investigate whether serum vasostatin-2 levels are related to restenosis in patients following percutaneous coronary intervention (PCI), and whether this peptide influences vascular neointimal hyperplasia in a mouse model of femoral artery injury. Methods and results Serum vasostatin-2 levels were evaluated in patients with (n = 442) and without (n = 442) restenosis after PCI. Recombinant vasostatin-2 or saline was administered in a mouse model of femoral artery injury. A combination of multi-omics (Bulk RNA sequencing, CUT&Tag detection, and glutathione S-transferase pull-down/mass spectrometry analysis) was employed to investigate underlying mechanisms. Patients with restenosis had lower serum vasostatin-2 levels than those without restenosis (P < 0.001). Vasostatin-2 protein significantly inhibited neointimal hyperplasia and suppressed the vascular smooth muscle cell (VSMC) phenotype switch after injury. Mechanistically, vasostatin-2 was proven to bind angiotensin-converting enzyme 2 (ACE2) and activate the downstream nuclear receptor subfamily 1 group D member 1 (NR1D1)-growth arrest-specific 1 (Gas1) pathway, thereby facilitating apoptosis of VSMCs and inhibiting their proliferation. ACE2-binding incompetent vasostatin-2 mutants and NR1D1 deficiency in VSMCs weakened vasostatin-2 effect on neointimal hyperplasia in mice.

Conclusion

Decreased serum vasostatin-2 levels are associated with coronary artery restenosis in patients with coronary angioplasty. Vasostatin-2 attenuates vascular injury-induced neointimal growth in mice and inhibits the proliferation of VSMCs in vitro through the ACE2/NR1D1/Gas1 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeointimaVascular System InjuriesMyocytes, Smooth MuscleMuscle, Smooth, VascularFemoral ArteryPeptide FragmentsProto-Oncogene ProteinsCoronary RestenosisChromogranin AAnimalsHyperplasiaSignal TransductionDisease Models, AnimalMaleHumansAngiotensin-Converting Enzyme 2Mice, Inbred C57BLCell ProliferationFemaleCells, CulturedMiddle AgedAgedProto-Oncogene MasPercutaneous Coronary InterventionVascular RemodelingMicePhenotype

Stichwörter der Autor:innen

Angiotensin-converting enzyme 2Neointimal hyperplasiaRestenosisVascular smooth muscle cellVasostatin-2

Substanzen

Angiotensin-Converting Enzyme 2Peptide FragmentsACE2 protein, humanProto-Oncogene ProteinsProto-Oncogene MasChromogranin A

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Institute of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Cardiology Division 1-Pisa University Hospital, University of Pisa, Pisa 56124, Italy.
  • National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

ORCID-Profile: Lin Lu, Raffaele De Caterina

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, Q., Liu, J., Madonna, R., Li, F., Chen, S., Li, L., Wu, X., Maimati, Y., Ding, F., Wang, X., Shen, Y., Zhang, R., Shen, W., Dai, Y., Lu, L., & De Caterina, R. (2025). Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf192

Vancouver

Chen Q, Liu J, Madonna R, Li F, Chen S, Li L, et al. Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf192

BibTeX
@article{Chen2025,
  author = {Chen, Qiujing and Liu, Jingmeng and Madonna, Rosalinda and Li, Feifei and Chen, Shuai and Li, Leying and Wu, Xinrui and Maimati, Yipaerguli and Ding, Fenghua and Wang, Xiaoqun and Shen, Ying and Zhang, Ruiyan and Shen, Weifeng and Dai, Yang and Lu, Lin and De Caterina, Raffaele},
  title = {Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis},
  journal = {Cardiovascular Research},
  year = {2025},
  doi = {10.1093/cvr/cvaf192}
}
Kostenlos starten →